Neonc Technologies (NASDAQ:NTHI) CMO Purchases $10,003.92 in Stock

Neonc Technologies Holdings, Inc. (NASDAQ:NTHI) CMO Thomas Chen purchased 2,284 shares of Neonc Technologies stock in a transaction that occurred on Tuesday, November 10th. The stock was acquired at an average price of $4.38 per share, for a total transaction of $10,003.92. Following the transaction, the chief marketing officer directly owned 29,519 shares of the company’s stock, valued at $129,293.22. The trade was a 8.39% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link.

Neonc Technologies Price Performance

Neonc Technologies stock traded up $0.06 during mid-day trading on Friday, reaching $4.91. 251,853 shares of the company’s stock traded hands, compared to its average volume of 118,828. The stock has a 50 day moving average of $3.30 and a two-hundred day moving average of $5.27. Neonc Technologies Holdings, Inc. has a 12-month low of $2.50 and a 12-month high of $11.38.

Neonc Technologies (NASDAQ:NTHI) last released its quarterly earnings data on Thursday, November 5th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.03).

Analyst Upgrades and Downgrades

NTHI has been the subject of a number of analyst reports. BTIG Research reaffirmed a “buy” rating and issued a $15.00 price target on shares of Neonc Technologies in a report on Tuesday, September 8th. Wall Street Zen raised Neonc Technologies from a “sell” rating to a “hold” rating in a research note on Saturday, November 7th. Zacks Research upgraded Neonc Technologies from a “strong sell” rating to a “hold” rating in a research report on Thursday, November 5th. Weiss Ratings lowered Neonc Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, October 21st. Finally, Roth Capital began coverage on Neonc Technologies in a research note on Thursday, September 24th. They issued a “buy” rating for the company. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $16.00.

Institutional Trading of Neonc Technologies

Several institutional investors have recently added to or reduced their stakes in NTHI. Global Retirement Partners LLC bought a new position in shares of Neonc Technologies during the second quarter valued at approximately $126,000. Marshall Wace LLP lifted its stake in shares of Neonc Technologies by 423.5% during the 3rd quarter. Marshall Wace LLP now owns 114,046 shares of the company’s stock worth $388,000 after acquiring an additional 92,262 shares during the last quarter. BlackRock Inc. purchased a new position in Neonc Technologies during the 2nd quarter valued at $815,000. Westmount Partners LLC boosted its holdings in Neonc Technologies by 355.2% during the 2nd quarter. Westmount Partners LLC now owns 197,178 shares of the company’s stock valued at $893,000 after acquiring an additional 153,858 shares during the period. Finally, Bank of America Corp DE purchased a new position in Neonc Technologies during the 2nd quarter valued at $1,017,000.

Neonc Technologies Company Profile

NeOnc Technologies Holdings, Inc. is a biotechnology company developing treatments for brain tumors and other central nervous system cancers. Its research focuses on approaches intended to deliver therapies to the brain, where the blood-brain barrier can limit the effectiveness of conventional treatments. The company’s pipeline includes NEO100, a formulation of perillyl alcohol designed for intranasal delivery, and NEO212, a compound combining perillyl alcohol with temozolomide. These candidates are being developed for potential use in brain cancer treatment.